by Administrators Qynapse | Aug 26, 2021 | News
BOSTON, MA, July 26, 2021 /PRNewswire/ – QYNAPSE Inc., a medical technology company commercializing an AI-powered and proprietary neuroimaging software platform, is attending the Alzheimer’s Association International Conference 2021 (AAIC) on July 26-30, 2021 in...
by Administrators Qynapse | Jun 22, 2021
The future of neuroimaging analysis is here and Qynapse is leading the way. For clinicians on the front lines, for patients and their families, for payers, and for pharma – we offer peace of mind by providing results you can trust. Patients Providers Payers Pharma...
by Administrators Qynapse | Jun 21, 2021
Together is the only way forward to an accurate future of diagnosis and treatment. Request a Demo Alone we stay exactly where we are. Together, we are moving forward to a brighter and more accurate future of diagnosis and treatment for central nervous system...
by Administrators Qynapse | Jun 18, 2021
Predictive technology to impact clinical trial design and outcomes CONTACT US ABOUT QYPREDICT® Available for research use only and protected by 3 patents, QyPredict® has the potential to improve targeted patient selection in clinical trials and prediction of disease...
by Administrators Qynapse | Jun 18, 2021
One scan at a time, QyScore® has the potential to revolutionize the treatment of CNS disease and create the potential for earlier precision on the frontlines of CNS disease. CONTACT US ABOUT QYSCORE® QyScore® is a groundbreaking neuroimaging analysis platform for both...
